AIM
VRTX icon

Achmea Investment Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Achmea Investment Management’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-15,934
Closed -$7.41M – 419
2024
Q3 		$7.41M Sell
15,934
-20,656
-56% -$9.92M 0.12% 186
2024
Q2 		$17.1M Sell
36,590
-13,644
-27% -$5.92M 0.31% 81
2024
Q1 		$21M Buy
50,234
+2,555
+5% +$1.08M 0.4% 65
2023
Q4 		$19.4M Sell
47,679
-8,728
-15% -$3.22M 0.4% 59
2023
Q3 		$19.6M Buy
56,407
+235
+0.4% +$82.2K 0.43% 51
2023
Q2 		$19.8M Buy
56,172
+5,893
+12% +$1.99M 0.42% 56
2023
Q1 		$15.8M Sell
50,279
-1,115
-2% -$334K 0.46% 50
2022
Q4 		$13.9M Buy
51,394
+1,154
+2% +$352K 0.47% 48
2022
Q3 		$14.5M Buy
50,240
+12,680
+34% +$3.65M 0.51% 40
2022
Q2 		$10.6M Buy
37,560
+1,428
+4% +$382K 0.34% 64
2022
Q1 		$9.43M Buy
+36,132
New +$8.58M 0.25% 99
2021
Q4 		– Sell
-37,930
Closed -$6.88M – 616
2021
Q3 		$6.88M Sell
37,930
-2,988
-7% -$583K 0.21% 135
2021
Q2 		$8.25M Buy
40,918
+24,984
+157% +$5.23M 0.28% 93
2021
Q1 		$3.42M Hold
15,934
– – 0.12% 228
2020
Q4 		$3.77M Hold
15,934
– – 0.14% 189
2020
Q3 		$4.34M Sell
15,934
-22,350
-58% -$6.17M 0.18% 149
2020
Q2 		$11.1M Buy
+38,284
New +$10.4M 0.38% 60
2020
Q1 		– Sell
-14,663
Closed -$3.21M – 551
2019
Q4 		$3.21M Hold
14,663
– – 0.12% 189
2019
Q3 		$2.48M Hold
14,663
– – 0.1% 228
2019
Q2 		$2.69M Sell
14,663
-368
-2% -$64.3K 0.1% 226
2019
Q1 		$2.77M Hold
15,031
– – 0.12% 200
2018
Q4 		$2.49M Buy
15,031
+720
+5% +$125K 0.12% 197
2018
Q3 		$2.76M Sell
14,311
-2,612
-15% -$465K 0.1% 225
2018
Q2 		$2.88M Hold
16,923
– – 0.1% 235
2018
Q1 		$2.76M Hold
16,923
– – 0.09% 248
2017
Q4 		$2.54M Buy
16,923
+5,420
+47% +$803K 0.09% 268
2017
Q3 		$1.75M Buy
11,503
+2,835
+33% +$427K 0.1% 257
2017
Q2 		$1.12M Buy
8,668
+3,507
+68% +$422K 0.07% 316
2017
Q1 		$564K Buy
+5,161
New +$454K 0.03% 427

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Achmea Investment Management's VRTX Position: Q4 2024 in Review

Achmea Investment Management sold out of Vertex Pharmaceuticals (VRTX) in Q4 2024, closing a stake of 15,934 shares — an estimated $7.41M sold.

Achmea Investment Management first reported a position in VRTX in Q1 2017 and held it in 29 quarters. The position peaked at $21M in Q1 2024. 1,562 funds tracked by Wall St. Rank hold VRTX as of Q4 2024.

  • Achmea Investment Management reported no remaining Vertex Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • Achmea Investment Management sold 15,934 Vertex Pharmaceuticals shares in Q4 2024, an estimated $7.41M.
  • Achmea Investment Management first reported a position in Vertex Pharmaceuticals in Q1 2017 and held it in 29 quarters.
  • Achmea Investment Management's Vertex Pharmaceuticals position peaked at $21M in Q1 2024.
  • 1,562 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q4 2024.

Based on Achmea Investment Management's 13F filing for Q4 2024, filed 10 Feb 2025.